AngioDynamics announced European CE Mark approval of the Auryon Atherectomy System, an innovative technology for the treatment of Peripheral Artery Disease, PAD, including Critical Limb Ischemia, CLI, and In-Stent Restenosis, ISR.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANGO:
- TipRanks ‘Perfect 10’ List: 2 Top-Scoring Stocks Worth Watching
- AngioDynamics price target lowered to $13 from $18 at Canaccord
- AngioDynamics Unveils Fiscal Achievements and Growth Plans
- AngioDynamics sees FY25 adjusted EPS (42c)-(38c), consensus (49c)
- AngioDynamics reports Q4 adjusted EPS (5c), consensus (16c)